Zoledronate, fractures, and mortality after hip fracture [1]

New England Journal of Medicine

Volumn 358, Issue 9, 2008, Pages 967-969

  Van Den Berg, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; CALCITONIN; HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

CLINICAL TRIAL; DRUG EFFECT; HIP FRACTURE; HUMAN; INJURY SEVERITY; LETTER; MORTALITY; POSTMENOPAUSE OSTEOPOROSIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME; VERTEBRA FRACTURE; CHEMICALLY INDUCED DISORDER; EPIDEMIOLOGY; FRACTURE; HEART ATRIUM FIBRILLATION; NOTE; METHODOLOGY; RISK; CARDIOTOXICITY;

ATRIAL FIBRILLATION; BONE DENSITY CONSERVATION AGENTS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIPHOSPHONATES; FRACTURES, BONE; HIP FRACTURES; HUMANS; IMIDAZOLES; RESEARCH DESIGN; RISK;

EID: 85048354606     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc073292     Document Type: Letter

References (1)

1. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.